Dare Bioscience, Inc. Business Combination, Contingent Consideration, Liability, Current
Dare Bioscience, Inc. (DARE) had Business Combination, Contingent Consideration, Liability, Current of $0 as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2022-03-31
- 2021-12-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2021-09-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2021-06-30: Business Combination, Contingent Consideration, Liability, Current $1.00M.
- 2021-03-31: Business Combination, Contingent Consideration, Liability, Current $1.00M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.00M 10-K · filed 2022-03-31 |
| 2020-09-30 | $1.00M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |